In Vivo Assessment of an Oral Therapeutic for Celiac Disease

Focus: 

To conduct preclinical testing and development of a gluten-digesting oral therapy for celiac disease

Anticipated Impact: 

Protection of celiac disease patients from accidental ingestion of gluten

Abstract: 

Celiac disease, an autoimmune disease, cannot currently be prevented or treated; complete avoidance of gluten, which is very difficult, is the only intervention. The proposed product, KumaMax, would be taken orally when a person is concerned that a meal will contain gluten. Digestion of gluten would occur before it causes the immune reaction. KumaMax will be evaluated using customary drug development methods, including toxicity and dosage determination in an animal model, in preparation for human trials. KumaMax is one of the earliest commercialization efforts of the Institute for Protein Design, funded in part by LSDF. A startup company, PVP Biologics, will be launched to commercialize KumaMax. Matching funds will come from private philanthropists and a crowd-funding campaign.

Collaborating organization: University of Mainz, Germany

Trisha Davis replaced Ingrid Pultz as principal investigator in February 2017.

Celiac Disease Therapy

Grant Update

Principal Investigator:
Trisha Davis
Grantee Organization:
University of Washington
Grant Title:
In Vivo Assessment of an Oral Therapeutic for Celiac Disease
Grant Cohort and Year:
2015 Matching (05)
Grant Period:
04/16/2015 - 04/15/2017 (Completed)
Grant Amount:
$250,000
With LSDF funds, we have established a clinical program and initiated work on that program; identified and developed an organism to produce our drug at lower cost, and attracted financing to further this work outside of academia.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact
Seattle

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Celiac Disease Therapy

Nov 10, 2015
Investing.com
Jan 29, 2015
University of Washington Daily